Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Pulmonary Hypertension

Free Subscription Articles published in Circulation Retrieve available abstracts of 57 articles: HTML format

Single Articles

March 2026
1. FORBES LM, Cornwell WK
   Group 1 Pulmonary Hypertension With Elevated Pulmonary Artery Wedge Pressure: Characterizing A Complex Phenotype.
   Circulation. 2026;153:963-966.
   PubMed    
   
   
   
2. GOMBERG-MAITLAND M, Tedford RJ, Langleben D, Rosenkranz S, et al
   Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
   Circulation. 2026 Mar 29. doi: 10.1161/CIRCULATIONAHA.126.079918.
   PubMed     Abstract available
   
   
   February 2026
3. REDDY YNV, Frantz RP, Miranda WR, Asokan AK, et al
   Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension.
   Circulation. 2026 Feb 13. doi: 10.1161/CIRCULATIONAHA.125.077606.
   PubMed     Abstract available
   
   
   
4. JAMBON-BARBARA C, Suissa S, Dell'Aniello S, Hlavaty A, et al
   Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.
   Circulation. 2026 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.077764.
   PubMed     Abstract available
   
   
   January 2026
5. TORO V, Mougin M, Brossat C, Jambon-Barbara C, et al
   Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.
   Circulation. 2026 Jan 28. doi: 10.1161/CIRCULATIONAHA.125.079067.
   PubMed     Abstract available
   
   
   
6. TADA A, Fayyaz AU, Reddy YNV, Redfield MM, et al
   Rapidly Progressive Pulmonary Hypertension: Importance of Vascular Disease Distribution.
   Circulation. 2026;153:285-289.
   PubMed    
   
   
   April 2025
7. YU Q, Tai YY, Tang Y, Zhao J, et al
   Correction to: BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.
   Circulation. 2025;151:e967.
   PubMed    
   
   
   March 2025
8. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
   Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
   Circulation. 2025;151:e763.
   PubMed    
   
   
   
9. DAI H, Lu X, Zhou X
   Letter by Dai et al Regarding Article, "Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction".
   Circulation. 2025;151:e686.
   PubMed    
   
   
   January 2025
10. LEMAY SE, Montesinos MS, Grobs Y, Yokokawa T, et al
    Exploring Integrin alpha5beta1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies.
    Circulation. 2025 Jan 20. doi: 10.1161/CIRCULATIONAHA.124.070693.
    PubMed     Abstract available
    
    
    November 2024
11. MCLAUGHLIN VV, Humbert M
    Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions.
    Circulation. 2024;150:1653-1655.
    PubMed    
    
    
    October 2024
12. DELCROIX M, Pepke-Zaba J, D'Armini AM, Fadel E, et al
    Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy.
    Circulation. 2024;150:1354-1365.
    PubMed     Abstract available
    
    
    August 2024
13. HONG J, Medzikovic L, Sun W, Wong B, et al
    Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension.
    Circulation. 2024 Aug 21. doi: 10.1161/CIRCULATIONAHA.124.069864.
    PubMed     Abstract available
    
    
    July 2024
14. LIU B, Yi D, Xia X, Ramirez K, et al
    General Capillary Endothelial Cells Undergo Reprogramming Into Arterial Endothelial Cells in Pulmonary Hypertension Through HIF-2alpha/Notch4 Pathway.
    Circulation. 2024;150:414-417.
    PubMed    
    
    
    June 2024
15. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069340.
    PubMed     Abstract available
    
    
    
16. ZHANG Q, Yaoita N, Tabuchi A, Liu S, et al
    Endothelial Heterogeneity in the Response to Autophagy Drives Small Vessel Muscularization in Pulmonary Hypertension.
    Circulation. 2024 Jun 14. doi: 10.1161/CIRCULATIONAHA.124.068726.
    PubMed     Abstract available
    
    
    
17. 
    Correction to: Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024;149:e1412.
    PubMed    
    
    
    May 2024
18. SALAHUDDIN A, Harris IS, Sabanayagam A
    Double Whammy Complicating Management of Pulmonary Hypertension.
    Circulation. 2024;149:1770-1774.
    PubMed    
    
    
    
19. JHENG JR, Bai Y, Noda K, Huot JR, et al
    Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 May 28. doi: 10.1161/CIRCULATIONAHA.124.068624.
    PubMed     Abstract available
    
    
    
20. HOEPER MM, Ewert R, Jansa P, Sirenko Y, et al
    Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
    Circulation. 2024 May 16. doi: 10.1161/CIRCULATIONAHA.123.068107.
    PubMed     Abstract available
    
    
    
21. RUBIN LJ
    Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?
    Circulation. 2024;149:1565-1567.
    PubMed    
    
    
    
22. TANG H, Gupta A, Morrisroe SA, Bao C, et al
    Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension.
    Circulation. 2024 May 2. doi: 10.1161/CIRCULATIONAHA.123.065304.
    PubMed     Abstract available
    
    
    April 2024
23. BORDAN Z, Batori R, Haigh S, Li X, et al
    PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension.
    Circulation. 2024 Apr 29. doi: 10.1161/CIRCULATIONAHA.123.067095.
    PubMed     Abstract available
    
    
    
24. RAO RJ, Chan SY
    Mediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension.
    Circulation. 2024;149:1372-1374.
    PubMed    
    
    
    
25. GERHARDT F, Fiessler E, Olsson KM, Kayser MZ, et al
    Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
    Circulation. 2024 Apr 12. doi: 10.1161/CIRCULATIONAHA.122.063821.
    PubMed     Abstract available
    
    
    
26. SHEN H, Gao Y, Ge D, Tan M, et al
    BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.
    Circulation. 2024 Apr 1. doi: 10.1161/CIRCULATIONAHA.123.066430.
    PubMed     Abstract available
    
    
    March 2024
27. AGGARWAL V, Giri J, Visovatti SH, Mahmud E, et al
    Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Mar 7. doi: 10.1161/CIR.0000000000001197.
    PubMed     Abstract available
    
    
    February 2024
28. LUO Y, Qi X, Zhang Z, Zhang J, et al
    Inactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary Hypertension.
    Circulation. 2024 Feb 5. doi: 10.1161/CIRCULATIONAHA.123.067579.
    PubMed     Abstract available
    
    
    January 2024
29. BIAN JS, Chen J, Zhang J, Tan J, et al
    ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension.
    Circulation. 2024 Jan 12. doi: 10.1161/CIRCULATIONAHA.123.067005.
    PubMed     Abstract available
    
    
    November 2023
30. WALTERS R, Vasilaki E, Wilkins MR, Zhao L, et al
    Response by Walters et al to Letter Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension".
    Circulation. 2023;148:1825-1826.
    PubMed    
    
    
    
31. LI G, Chen H, Ren C
    Letter by Li et al Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension".
    Circulation. 2023;148:1823-1824.
    PubMed    
    
    
    
32. HOSOKAWA K, Watanabe H, Taniguchi Y, Ikeda N, et al
    A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528.
    PubMed    
    
    
    September 2023
33. KUEHN BM
    Experimental Drug, Combination Pill Show Promise for Treating Pulmonary Hypertension.
    Circulation. 2023;148:852-854.
    PubMed    
    
    
    July 2023
34. 
    Correction to: Heteroplasmy of Wild-Type Mitochondrial DNA Variants in Mice Causes Metabolic Heart Disease With Pulmonary Hypertension and Frailty.
    Circulation. 2023;148:e2.
    PubMed    
    
    
    May 2023
35. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
    Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
    Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
    PubMed     Abstract available
    
    
    
36. 
    Correction to: Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension.
    Circulation. 2023;147:e718.
    PubMed    
    
    
    April 2023
37. GUIGNABERT C, Savale L, Boucly A, Thuillet R, et al
    Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension.
    Circulation. 2023 Apr 25. doi: 10.1161/CIRCULATIONAHA.122.061501.
    PubMed     Abstract available
    
    
    
38. WALTERS R, Vasilaki E, Aman J, Chen CN, et al
    SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.
    Circulation. 2023 Apr 17. doi: 10.1161/CIRCULATIONAHA.122.061940.
    PubMed     Abstract available
    
    
    March 2023
39. RAJAGOPAL S, Ruetzler K, Ghadimi K, Horn EM, et al
    Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association.
    Circulation. 2023 Mar 16. doi: 10.1161/CIR.0000000000001136.
    PubMed     Abstract available
    
    
    February 2023
40. CHIN KM, Santiago-Munoz P
    Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?
    Circulation. 2023;147:562-564.
    PubMed    
    
    
    
41. ZHANG Q, Zhu F, Shi G, Hu C, et al
    Maternal Outcomes Among Pregnant Women With Congenital Heart Disease-Associated Pulmonary Hypertension.
    Circulation. 2023;147:549-561.
    PubMed     Abstract available
    
    
    December 2022
42. BORN E, Lipskaia L, Breau M, Houssaini A, et al
    Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
    Circulation. 2022 Dec 14. doi: 10.1161/CIRCULATIONAHA.122.058794.
    PubMed     Abstract available
    
    
    November 2022
43. ZHOU W, Liu K, Zeng L, He J, et al
    Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.
    Circulation. 2022 Nov 17. doi: 10.1161/CIRCULATIONAHA.122.061900.
    PubMed     Abstract available
    
    
    
44. JHA AK
    Letter by Jha Regarding Article, "Latent Pulmonary Vascular Disease and Therapeutic Atrial Shunt".
    Circulation. 2022;146:e242-e243.
    PubMed    
    
    
    
45. BORLAUG BA, Shah SJ
    Response by Borlaug and Shah Regarding Article, "Latent Pulmonary Vascular Disease and Therapeutic Atrial Shunt".
    Circulation. 2022;146:e244-e245.
    PubMed    
    
    
    September 2022
46. ZHONG Y, Yu PB
    Decoding the Link Between Inflammation and Pulmonary Arterial Hypertension.
    Circulation. 2022;146:1023-1025.
    PubMed    
    
    
    
47. 
    Correction to: Nanoparticle Delivery of STAT3 Alleviates Pulmonary Hypertension in a Mouse Model of Alveolar Capillary Dysplasia.
    Circulation. 2022;146:e168.
    PubMed    
    
    
    August 2022
48. BRUSCA SB, Elinoff JM, Zou Y, Jang MK, et al
    Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.
    Circulation. 2022 Aug 25:101161CIRCULATIONAHA121056719.
    PubMed     Abstract available
    
    
    
49. YAKU A, Inagaki T, Asano R, Okazawa M, et al
    Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
    Circulation. 2022 Aug 23:101161CIRCULATIONAHA122059435.
    PubMed     Abstract available
    
    
    
50. RUFFENACH G, Medzikovic L, Aryan L, Li M, et al
    HNRNPA2B1: RNA-Binding Protein That Orchestrates Smooth Muscle Cell Phenotype in Pulmonary Arterial Hypertension.
    Circulation. 2022 Aug 22:101161CIRCULATIONAHA122059591.
    PubMed     Abstract available
    
    
    
51. STEFFES LC, Cheng P, Quertermous T, Kumar ME, et al
    von Willebrand Factor Is Produced Exclusively by Endothelium, Not Neointima, in Occlusive Vascular Lesions in Both Pulmonary Hypertension and Atherosclerosis.
    Circulation. 2022;146:429-431.
    PubMed    
    
    
    
52. JIN Q, Guan L, Zhou D
    Letter by Jin et al Regarding Article, "SPARC, A Novel Regulator of Vascular Cell Function in Pulmonary Hypertension".
    Circulation. 2022;146:e14-e15.
    PubMed    
    
    
    
53. VEITH C, Ghofrani HA, Weissmann N
    Response by Veith et al to Letter Regarding Article, "SPARC, A Novel Regulator of Vascular Cell Function in Pulmonary Hypertension".
    Circulation. 2022;146:e16-e17.
    PubMed    
    
    
    July 2022
54. BRITTAIN EL, Thenappan T, Huston JH, Agrawal V, et al
    Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.
    Circulation. 2022 Jul 11:101161CIR0000000000001079.
    PubMed     Abstract available
    
    
    
55. TREMBLAY E, Gosselin C, Mai V, Lajoie AC, et al
    Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Circulation. 2022 Jul 8:101161CIRCULATIONAHA121058635.
    PubMed     Abstract available
    
    
    March 2022
56. STEWART RH, Cox CS Jr, Allen SJ, Laine GA, et al
    Myocardial Edema Provides a Link Between Pulmonary Arterial Hypertension and Pericardial Effusion.
    Circulation. 2022;145:793-795.
    PubMed    
    
    
    
57. LECHUGA-VIECO AV, Latorre-Pellicer A, Calvo E, Torroja C, et al
    Heteroplasmy of Wild Type Mitochondrial DNA Variants in Mice Causes Metabolic Heart Disease With Pulmonary Hypertension and Frailty.
    Circulation. 2022 Mar 3. doi: 10.1161/CIRCULATIONAHA.121.056286.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum